SP
BravenNow
Form 6K Innate Pharma For: 18 February
| USA | economy | ✓ Verified - investing.com

Form 6K Innate Pharma For: 18 February

#Innate Pharma #Form 6‑K #SEC filing #February #Corporate governance #Financial reporting

📌 Key Takeaways

  • Issuer: Innate Pharma
  • Form type: 6‑K (Regulatory filing)
  • Filing date: 18 February
  • Purpose: to disclose material corporate information to investors
  • Submission: with the U.S. Securities and Exchange Commission

📖 Full Retelling

On 18 February, Innate Pharma filed a Form 6‑K with the U.S. Securities and Exchange Commission. This filing was submitted to disclose material corporate developments and other information that may be relevant to investors. The Form 6‑K, a standard regulatory instrument for U.S. public companies, is used to report updates on events, regulatory changes, financial results or other information that could impact the company’s valuation.

🏷️ Themes

Regulatory compliance, Corporate disclosure, Investor transparency

Entity Intersection Graph

No entity connections available yet for this article.

}

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine